Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

by | May 14, 2026 | Uncategorized

Spread the love
Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments